Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.

Blood - 6 Oct 2011

Braun Thorsten, Itzykson Raphael, Renneville Aline, de Renzis Benoit, Dreyfus François, Laribi Kamel, Bouabdallah Krimo, Vey Norbert, Toma Andrea, Recher Christian, Royer Bruno, Joly Bertrand, Vekhoff Anne, Lafon Ingrid, Sanhes Laurence, Meurice Guillaume, Oréar Cédric, Preudhomme Claude, Gardin Claude, Ades Lionel, Fontenay Michaela, Fenaux Pierre, Droin Nathalie, Solary Eric

Abstract excerpt

Hydroxyurea is the standard therapy of chronic myelomonocytic leukemia (CMML) presenting with advanced myeloproliferative and/or myelodysplastic features. Response to hypomethylating agents has been reported in heterogeneous series of CMML. We conducted a phase 2 trial of decitabine (DAC) in 39 p...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Antimetabolites, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Azacitidine

Share to Decitabine

Share to Gene Expression Regulation, Leukemic

Share to Leukemia, Myelomonocytic, Chronic

Share to Prognosis

Share to Survival Analysis

Source

Identifiers

PMID: 21828134
DOI: 10.1182/blood-2011-05-352039

Genes

ASXL1
CBL
FLT3
JAK2
KRAS
NRAS
TET2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21828134-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.PMID 21828134Read ↗

Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemiaSemantic proximity Read ↗

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.Semantic proximity Read ↗

Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemiaSemantic proximity Read ↗

Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.Semantic proximity Read ↗

Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemiaSemantic proximity Read ↗

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.Semantic proximity Read ↗

Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes.Semantic proximity Read ↗

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.Semantic proximity Read ↗

Mechanism of response to FHD-286 and decitabine combination in patients with advanced myeloid malignanciesSemantic proximity Read ↗

Emerging drugs for the treatment of chronic myelomonocytic leukemia.Semantic proximity Read ↗

Outcome of patients with accelerated and blast‐phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination—A FIM studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.